• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过使用历史对照物减轻临床试验中的患者负担:适当选择历史数据以最小化偏倚风险。

Reducing Patient Burden in Clinical Trials Through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias.

机构信息

Clinical Statistics, GSK, 1250 S. Collegeville Road, Collegeville, PA, 19426-0989, USA.

Data and Statistical Sciences, Abbvie, North Chicago, IL, USA.

出版信息

Ther Innov Regul Sci. 2020 Jul;54(4):850-860. doi: 10.1007/s43441-019-00014-4. Epub 2019 Dec 10.

DOI:10.1007/s43441-019-00014-4
PMID:32557308
Abstract

Historical data have been used to augment or replace control arms in some rare disease and pediatric clinical trials. With greater availability of historical data and new methodology such as dynamic borrowing, the inclusion of historical data in clinical trials is an increasingly appealing approach for larger disease areas as well, as this can result in increased power and precision and can minimize the burden on patients in clinical trials. However, sponsors must assess whether the potential biases incurred with this approach outweigh the benefits and discuss this trade-off with the regulatory agencies. This paper discusses important points for the appropriate selection of historical controls for inclusion in the analysis of primary and/or key secondary endpoint(s) in clinical trials. The general steps are as follows: (1) Assess whether a trial is a suitable candidate for this approach. (2) If it is, then carefully identify appropriate historical trials to minimize selection bias. (3) Refine the historical control set if appropriate, for example, by selecting subsets of studies or patients. Identification of trial settings that are amenable to historical borrowing and selection of appropriate historical data using the principles discussed in this paper has the potential to lead to more efficient estimation and decision making. Ultimately, this efficiency gain results in lower patient burden and gets effective drugs to patients more quickly.

摘要

历史数据已被用于某些罕见病和儿科临床试验中,以补充或替代对照组。随着历史数据的可用性增加,以及动态借用等新方法的出现,这种在临床试验中纳入历史数据的方法对于更大的疾病领域也越来越具有吸引力,因为这可以提高功效和精度,并最大限度地减少临床试验中患者的负担。然而,赞助商必须评估这种方法所带来的潜在偏差是否超过了益处,并与监管机构讨论这种权衡取舍。本文讨论了在临床试验中为纳入主要和/或次要终点分析而适当选择历史对照的重要要点。一般步骤如下:(1)评估试验是否适合采用这种方法。(2)如果适合,则仔细确定适当的历史试验,以最大程度地减少选择偏差。(3)如有必要,进一步完善历史对照集,例如,选择研究或患者的子集。本文讨论的原则可用于确定适合历史借用的试验环境,并选择适当的历史数据,这有可能提高估计和决策的效率。最终,这种效率的提高将降低患者的负担,并使有效的药物更快地惠及患者。

相似文献

1
Reducing Patient Burden in Clinical Trials Through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias.通过使用历史对照物减轻临床试验中的患者负担:适当选择历史数据以最小化偏倚风险。
Ther Innov Regul Sci. 2020 Jul;54(4):850-860. doi: 10.1007/s43441-019-00014-4. Epub 2019 Dec 10.
2
Dynamic use of historical controls in clinical trials for rare disease research: A re-evaluation of the MILES trial.在罕见病研究的临床试验中动态使用历史对照:对 MILES 试验的重新评估。
Clin Trials. 2023 Jun;20(3):223-234. doi: 10.1177/17407745231158906. Epub 2023 Mar 17.
3
Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and Opportunities.在创新性确证性临床试验中利用历史受试者水平数据减轻患者负担:方法与机遇综述
Ther Innov Regul Sci. 2018 Sep;52(5):546-559. doi: 10.1177/2168479018778282. Epub 2018 Jun 18.
4
Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.现行全球监管法规下罕见病的监管策略:利益相关者的讨论。
Orphanet J Rare Dis. 2019 Feb 8;14(1):36. doi: 10.1186/s13023-019-1017-5.
5
Borrowing from Historical Control Data in Cancer Drug Development: A Cautionary Tale and Practical Guidelines.癌症药物研发中借鉴历史对照数据:一则警示故事与实用指南
Stat Biopharm Res. 2019;11(1):67-78. doi: 10.1080/19466315.2018.1497533. Epub 2019 Apr 22.
6
The project data sphere initiative: accelerating cancer research by sharing data.项目数据领域计划:通过数据共享加速癌症研究
Oncologist. 2015 May;20(5):464-e20. doi: 10.1634/theoncologist.2014-0431. Epub 2015 Apr 15.
7
Supplementation of a clinical trial by historical control data: is the prospect of dynamic borrowing an illusion?通过历史对照数据补充临床试验:动态借用前景是否只是一种幻想?
Stat Med. 2017 Mar 15;36(6):899-916. doi: 10.1002/sim.7180. Epub 2016 Dec 7.
8
Utilizing shared internal control arms and historical information in small-sized platform clinical trials.在小型平台临床试验中利用共享的内部对照臂和历史信息。
J Biopharm Stat. 2019;29(5):845-859. doi: 10.1080/10543406.2019.1657132. Epub 2019 Aug 28.
9
A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG).在临床试验中使用历史对照的路线图 - 药物信息协会适应性设计科学工作组(DIA-ADSWG)。
Orphanet J Rare Dis. 2020 Mar 12;15(1):69. doi: 10.1186/s13023-020-1332-x.
10
Minimizing control group allocation in randomized trials using dynamic borrowing of external control data - An application to second line therapy for non-small cell lung cancer.利用外部对照数据的动态借用在随机试验中尽量减少对照组分配——在非小细胞肺癌二线治疗中的应用
Contemp Clin Trials Commun. 2019 Sep 9;16:100446. doi: 10.1016/j.conctc.2019.100446. eCollection 2019 Dec.

引用本文的文献

1
Current and Emerging Therapies for Lysosomal Storage Disorders.溶酶体贮积症的现有及新兴疗法
Drugs. 2025 Feb;85(2):171-192. doi: 10.1007/s40265-025-02145-5. Epub 2025 Jan 18.
2
Using Bayesian Dynamic Borrowing to Maximize the Use of Existing Data: A Case-Study.利用贝叶斯动态借用最大化现有数据的利用:一个案例研究。
Ther Innov Regul Sci. 2024 Jan;58(1):1-10. doi: 10.1007/s43441-023-00585-3. Epub 2023 Nov 1.
3
On the use of non-concurrent controls in platform trials: a scoping review.在平台试验中使用非同期对照:范围综述。
Trials. 2023 Jun 15;24(1):408. doi: 10.1186/s13063-023-07398-7.
4
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia.一项针对人组织因子途径抑制剂的马司他丁单抗的 1b/2 期临床研究在血友病中的应用。
Br J Haematol. 2023 Jan;200(2):229-239. doi: 10.1111/bjh.18420. Epub 2022 Aug 23.
5
Estimands and Complex Innovative Designs.估算目标和复杂创新设计。
Clin Pharmacol Ther. 2022 Dec;112(6):1183-1190. doi: 10.1002/cpt.2575. Epub 2022 Mar 29.
6
What Do Placebo and Nocebo Effects Have to Do With Health Equity? The Hidden Toll of Nocebo Effects on Racial and Ethnic Minority Patients in Clinical Care.安慰剂和反安慰剂效应与健康公平有何关系?临床护理中反安慰剂效应给种族和少数民族患者带来的隐性代价。
Front Psychol. 2021 Dec 23;12:788230. doi: 10.3389/fpsyg.2021.788230. eCollection 2021.
7
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.甘特纳单抗或 Solanezumab 治疗显性遗传性阿尔茨海默病的临床试验。
Nat Med. 2021 Jul;27(7):1187-1196. doi: 10.1038/s41591-021-01369-8. Epub 2021 Jun 21.
8
Summarising salient information on historical controls: A structured assessment of validity and comparability across studies.总结历史对照研究中的重要信息:对各研究间的有效性和可比性进行结构化评估。
Clin Trials. 2020 Dec;17(6):607-616. doi: 10.1177/1740774520944855. Epub 2020 Sep 21.